glp 1 agonist black box warning FDA Says to Drop Suicide From GLP-1 Drug Labels GLP-1 benefits, and the rising

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results

Kits for blood analysis were purchased from Biodiagnostic Co Egypt

Wide complex tachycardia should be presumed to be ventricular tachycardia when the diagnosis is unclearparticularly if it occurs in the presence of structural heart diseaseand requires further evaluation

No necesariamente

A study shows that L-carnitine increases PINK1-Parkin-dependent mitophagy and reduces microvascular dysfunction in DCM via the CPT1a-PHB2-PARL pathway in high glucose and free fatty acid (HG/FFA)-induced human cardiac microvascular endothelial cell (HCMEC) and db/db mouse model [180]